Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1998 Oct;89(10):1047–1054. doi: 10.1111/j.1349-7006.1998.tb00495.x

Different Effects of FK317 on Multidrug‐resistant Tumor in vivo and in vitro

Yoshinori Naoe 1,✉, Masamichi Inami 1, Shoji Takagaki 1, Sanae Matsumoto 1, Ikuo Kawamura 1, Fusako Nishigaki 1, Susumu Tsujimoto 1, Toshitaka Manda 1, Kyoichi Shimomura 1
PMCID: PMC5921702  PMID: 9849584

Abstract

FK317, a novel substituted dihydrobenzoxazine, was examined for antitumor effects on multidrug‐resistant (MDR) tumor cells in vitro and in vivo. In nude mice, FK317 markedly inhibited the growth of s.c. implanted KB‐V1 vinblastine (VLB)‐resistant human epidermal carcinoma KB cells, as well as the parent cells (KB‐3‐1). However, KB‐V1 showed much greater resistance to FK317 than to VLB and adriamycin (ADM) in the in vitro study. This resistance was reversed by the addition of verapamil, whereby intracellular accumulation of FK317 in the KB‐V1 cells was also decreased. After incubation of FK317 in human and mouse blood, it was shown to be rapidly metabolized to a monodeacetylated form, and slowly metabolized further to a dideacetylated form. With the removal of the acetyl groups from FK317, resistance indexes in KB‐V1 and SBC‐3/ADM, ADM‐resistant human lung carcinoma, decreased. In addition, photolabeling of P‐glycoprotein with [3H]azidopine in KB‐V1 plasma membrane was completely inhibited by FK317, but not by the deacetylated metabolites. These results indicate that FK317 is metabolized to deacetylated forms, which do not bind to P‐glycoprotein and are incorporated into MDR cells, causing cytotoxic effects.

Keywords: FK317, Antitumor effect, Deacetyl metabolite, MDR, P‐Glycoprotein

Full Text

The Full Text of this article is available as a PDF (148.7 KB).

REFERENCES

  • 1. ) Biedler , J. L.Genetic aspects of multidrug resistance . Cancer , 70 , 1799 – 1809 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Safa , A. R.Photoaffinity labeling of P‐glycoprotein in multidrug‐resistant cells . Cancer Invest. , 11 , 46 – 56 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Juliano , R. L. and Ling , V.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants . Biochim. Biophys. Acta , 455 , 152 – 162 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Kartner , N. , Riordan , J. R. and Ling , V.Cell surface P‐glycoprotein associated with multidrug resistance in mammalian cell lines . Science , 221 , 1285 – 1288 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Roninson , I. B. , Chin , J. E. , Choi , K. , Gros , P. , Housman , D. E. , Fojo , A. , Shen , D.‐W. , Gottesman , M. M. and Pastan , I.Isolation of human mdr DNA sequences amplified in multidrug resistant KB carcinoma cells . Proc. Natl. Acad. Sci. USA , 83 , 4538 – 4542 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. ) Chen , C. , Chin , J. E. , Ueda , K. , Clark , D. R. , Pastan , I. , Gottesman , M. M. and Roninson , I. B.Internal duplication and homology with bacterial transport protein in the mdr 1 (p‐glycoprotein) gene from multidrug‐resistant human cells . Cell , 47 , 381 – 389 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Gros , P. , Croop , J. and Housman , D.Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins . Cell , 47 , 371 – 380 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Gerlach , J. H. , Endicott , J. H. , Juranka , P. F. , Henderson , G. , Sarangi , F. , Deuchars , K. L. and Ling , V.Homology between P‐glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance . Nature , 324 , 485 – 489 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Hamada , H. and Tsuruo , T.Purification of the 170‐ to 180‐kilodalton membrane glycoprotein associated with multidrug resistance: the 170‐ to 180‐kilodalton membrane glycoprotein is an ATPase . J. Biol. Chem. , 263 , 1454 – 1458 ( 1988. ). [PubMed] [Google Scholar]
  • 10. ) Dano , K.Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells . Biochim. Biophys. Acta , 323 , 466 – 483 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Inaba , M. , Kobayashi , H. , Sakurai , Y. and Johnson , R. K.Active efflux of daunomycin and adriamycin in sensitive and resistant sublines of P388 leukemia . Cancer Res. , 39 , 2200 – 2203 ( 1979. ). [PubMed] [Google Scholar]
  • 12. ) Gros , P. , Neriah , Y. B. , Croop , J. M. and Housman , D. E.Isolation and expression of a complementary DNA that confers multidrug resistance . Nature , 323 , 728 – 731 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Shimomura , K. , Manda , T. , Mukumoto , S. , Masuda , K. , Nakamura , T. , Mizota , T. , Matsumoto , S. , Nishigaki , F. , Oku , T. , Mori , J. and Shibayama , F.Antitumor activity and hematotoxicity of a new, substituted dihydrobenzox‐azine, FK973, in mice . Cancer Res. , 48 , 1166 – 1172 ( 1988. ). [PubMed] [Google Scholar]
  • 14. ) Masuda , K. , Nakamura , T. , Mizota , T. , Mori , J. and Shimomura , K.Interstrand DNA‐DNA and DNA‐protein cross‐links by a new antitumor antibiotic, FK973, in L1210 cells . Cancer Res. , 48 , 5172 – 5177 ( 1988. ). [PubMed] [Google Scholar]
  • 15. ) Majima , H. , Hasegawa , K. , Fukuoka , M. , Furuse , K. , Wakui , A. , Furue , H. , Masaoka , T. , Hattori , T. , Taguchi , T. , Ogura , T. and Niitani , H.Phase I clinical and pharma‐cokinetic study of FK973 . Proc. Am. Soc. Clin. Oncol. , 9 , 78 ( 1990. ). [Google Scholar]
  • 16. ) Pazdur , R. , Ho , D. H. , Daugherty , K. , Bradner , W. T. , Krakoff , I. H. and Raber , M. N.Phase I trial of FK973: description of a delayed vascular leak syndrome . Invest. New Drugs , 9 , 337 – 382 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Naoe , Y. , Inami , M. , Matsumoto , S. , Nishigaki , F. , Tsujimoto , S. , Kawamura , I. , Miyayasu , K. , Manda , T. and Shimomura , K.FK317; a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome . Cancer Chemother. Pharmacol. , 42 , 31 – 36 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Ueyama , Y.Applications for research on cancer treatment methods using cancer characteristics . In“The Nude Mouse and Anticancer Drug Evaluation ,” ed. Nakamura T. , Sakurai Y. and Inaba M. , pp. 197 – 203 ( 1996. ). Central Institute for Experimental Animals Press; , Kawasaki . [Google Scholar]
  • 19. ) Shen , D.‐W. , Cardarelli , C. , Hwang , J. , Cornwell , M. , Richert , N. , Ishii , S. , Pastan , I. and Gottesman , M. M.Multiple drug‐resistant human KB carcinoma cells independently selected for high‐level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins . J. Biol. Chem. , 261 , 7762 – 7770 ( 1986. ). [PubMed] [Google Scholar]
  • 20. ) Kiura , K. , Ohnoshi , T. , Tabata , M. , Shibayama , T. and Kimura , I.Establishment of an adriamycin‐resistant sub‐line of human small cell lung cancer showing multifactorial mechanisms of resistance . Acta Med. Okayama , 47 , 191 – 197 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Mosmann , T.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays . J. Immunol. Methods , 65 , 55 – 63 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Sato , W. , Fukazawa , N. , Suzuki , T. , Yusa , K. and Tsuruo , T.Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS‐073 . Cancer Res. , 51 , 2420 – 2424 ( 1991. ). [PubMed] [Google Scholar]
  • 23. ) Ambudkar , S. V. , Lelong , I. H. , Zhang , J. , Cardarelli , C. O. , Gottesman , M. M. and Pastan , I.Partial purification and reconstitution of the human multidrug‐resistance pump: characterization of the drug‐stimulatable ATP hydrolysis . Proc. Natl. Acad. Sci. USA , 89 , 8472 – 8476 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. ) Lockridge , O. , Mottershaw , J. N. , Eckerson , H. W. and La Du , B. N.Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase . J. Pharmacol. Exp. Ther. , 215 , 1 – 8 ( 1980. ). [PubMed] [Google Scholar]
  • 25. ) Elbaum , D. and Nagel , R. L.Esterase activity of hemoglobin . J. Biol. Chem. , 256 , 2280 – 2283 ( 1981. ). [PubMed] [Google Scholar]
  • 26. ) Mizuno , K. , Furuhashi , Y. , Maeda , O. , Iwata , M. , Misawa , T. , Kawai , M. , Kano , T. and Tomoda , Y.Mitomycin C cross‐resistance induced by adriamycin in human ovarian cancer cell in vitro . Cancer Chemother. Pharmacol. , 26 , 333 – 339 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Wakusawa , S. , Nakamura , S. and Miyamoto , K.Establishment by adriamycin exposure of multidrug‐resistant rat ascites hepatoma AH130 cells showing low DT‐diaphorase activity and high cross resistance to mitomycins . Jpn. J. Cancer Res. , 88 , 88 – 96 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. ) Zamora , J. M. , Pearce , H. L. and Beck , W. T.Physical‐chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells . Mol. Pharmacol. , 33 , 454 – 462 ( 1988. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES